Eton Pharmaceuticals Announces FDA Approval and Upcoming Launch of KHINDIVI™, the First and Only FDA-Approved Hydrocortisone Oral Solution for Pediatric Patients

Eton Pharmaceuticals (ETON) announced FDA approval of KHINDIVI, the first oral hydrocortisone solution for pediatric patients with adrenocortical insufficiency, and expects to commercially launch the product the week of June 2nd. Eton anticipates combined peak sales of KHINDIVI and ALKINDI SPRINKLE exceeding $50 million annually, addressing a significant need for accurate dosing in children who struggle with tablets. The treatment will be exclusively distributed through Anovo, a specialty pharmacy; however, the label carries warnings about potential adverse reactions and is not approved for increased dosing during stress events.

Analysis

Eton Pharmaceuticals (ETON) has secured FDA approval for KHINDIVI, the first and only oral hydrocortisone solution for pediatric patients aged five and older with adrenocortical insufficiency, with a commercial launch planned for the week of June 2nd. This ready-to-use liquid formulation, designed to ensure accurate dosing and simplify administration for children, positions Eton to address an unmet medical need. The company projects combined peak annual sales for KHINDIVI and its existing product, ALKINDI SPRINKLE, to exceed $50 million, targeting an estimated 5,000 U.S. patients aged 5-17. Distribution will be exclusive through Anovo, a specialty pharmacy, supported by the Eton Cares Program. While the approval and rapid launch capability are positive, potential headwinds include significant safety warnings, such as risks of adrenal crisis, growth retardation, and increased infection susceptibility associated with hydrocortisone. KHINDIVI is also not approved for increased dosing during stress events, potentially limiting its utility. The exclusive distribution model could also present access challenges. Institutional investor activity in Q1 2025 shows a net positive sentiment, with 54 firms adding ETON shares versus 35 decreasing positions; notable additions include Stifel Financial Corp, Cannell Capital LLC, Susquehanna International Group, LLP, and Millennium Management LLC, while Mink Brook Asset Management LLC, Parkman Healthcare Partners LLC, and Wasatch Advisors LP reduced or exited their positions. Analyst sentiment is currently favorable, with B. Riley and Craig-Hallum issuing 'Buy' ratings in May 2025 and no 'Sell' ratings reported.

Key Decisions for Investors

• Investors should weigh the significant market opportunity and projected revenue growth from KHINDIVI's first-mover advantage against the product's specific limitations and safety concerns, which could impact physician adoption and patient uptake.
• Monitor early commercialization metrics post-June 2nd launch, including prescription volumes and feedback from pediatric endocrinologists, to assess market penetration and the effectiveness of the Anovo-exclusive distribution channel.
• Consider the mixed institutional holdings changes, where new significant stakes were initiated alongside complete divestitures, and factor in the positive analyst ratings while remaining cognizant of the detailed risk profile outlined in the product's safety information.